Date: 2014-10-28
Type of information: Nomination
Compound: vice president
Company: Juventas Therapeutics (USA - OH)
Therapeutic area: Cardiovascular diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On October 28, 2014, Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease announced that Troy Ignelzi has joined the company as Senior Vice President of Finance and Operations. Troy brings 20 years in finance, operations, and business development experience with start-up and established life sciences companies. Mr. Ignelzi joins Juventas from YES Pharmaceuticals where he was Sr. Vice President of Business Development. In addition to global business development, he was responsible for financing engagements and provided strategic guidance to multiple clients’ SEC filings and subsequent successful IPOs. Prior to YES, Mr. Ignelzi held executive management positions at Esperion Therapeutics and Insys Therapeutics where he transitioned both organizations from early stage start-up through mid-stage publicly traded companies. He has helped raise over $200 million through both private placements and IPOs and provided operational leadership to advance their therapeutic platforms through key clinical development milestones.
Financial terms:
Latest news:
Is general: Yes
